A genome-wide association study of inflammatory biomarker changes in response to fenofibrate treatment in the Genetics of Lipid Lowering Drug and Diet Network-Reference-Cited by-同舟云学术

A genome-wide association study of inflammatory biomarker changes in response to fenofibrate treatment in the Genetics of Lipid Lowering Drug and Diet Network

Published:2012-03 Issue:3 Volume:22 Page:191-197
ISSN:1744-6872
Container-title:Pharmacogenetics and Genomics
language:en
Short-container-title:

Author:

Aslibekyan Stella,Kabagambe Edmond K.,Irvin Marguerite R.,Straka Robert J.,Borecki Ingrid B.,Tiwari Hemant K.,Tsai Michael Y.,Hopkins Paul N.,Shen Jian,Lai Chao-Qiang,Ordovas Jose M.,Arnett Donna K.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Genetics(clinical),Genetics,Molecular Biology,Molecular Medicine,General Pharmacology, Toxicology and Pharmaceutics

Reference29 articles.

1. Impact of genetic and environmental factors on hsCRP concentrations and response to therapeutic agents.;Shen;Clin Chem,2009

2. Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome-activated receptor-gamma agonists.;Libby;Am J Cardiol,2007

3. Effect of apolipoprotein E, peroxisome proliferator-activated receptor alpha and lipoprotein lipase gene mutations on the ability of fenofibrate to improve lipid profiles and reach clinical guideline targets among hypertriglyceridemic patients.;Brisson;Pharmacogenetics,2002

4. Pharmacogenetics and pharmacogenomics of cholesterol-lowering therapy.;Schmitz;Curr Opin Lipidol,2007

5. Apolipoprotein B genetic variants modify the response to fenofibrate: a GOLDN study.;Wojczynski;J Lipid Res,2010

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardiovascular Pharmacogenetics: From Discovery of Genetic Association to Clinical Adoption of Derived Test;Pharmacological Reviews;2024-08-09

2. Role of fenofibrate in multiple sclerosis;European Journal of Medical Research;2024-02-09

3. A 6-CpG validated methylation risk score model for metabolic syndrome: The HyperGEN and GOLDN studies;PLOS ONE;2021-11-15

4. A 6-CpG Validated Methylation Risk Score Model for Metabolic Syndrome: The HyperGEN and GOLDN Studies;2021-10-25

5. COMMD10 inhibits tumor progression and induces apoptosis by blocking NF‐κB signal and values up BCLC staging in predicting overall survival in hepatocellular carcinoma;Clinical and Translational Medicine;2021-05